Siemens Healthineers MAGNETOM MRI Systems Advance with Imaginostics Letter of Support for Quantitative Imaging

Siemens Healthineers has issued a Letter of Support to Imaginostics, opening doors for quantitative MRI integration into MAGNETOM systems. This step toward AI-driven biomarkers promises enhanced diagnostic precision, positioning the technology as a leader in Europe's growing precision medicine market.

Siemens Healthineers issued a Letter of Support to Imaginostics on March 20, 2026, signaling exploratory discussions for integrating quantitative MRI technologies into its MAGNETOM systems. This development matters now because it advances AI-powered imaging biomarkers, making MRI scans more objective and reproducible for clinical use. DACH investors should care as it strengthens Siemens Healthineers' competitive edge in the high-growth medical imaging sector, where precision diagnostics drive demand in advanced healthcare systems.

Updated: 21.03.2026

Dr. Elena Müller, Senior Editor for Medical Imaging and Health Tech, covering innovations that shape diagnostic futures in the DACH region's leading hospitals and clinics.

Letter of Support Initiates Quantitative MRI Collaboration

The Letter of Support from Siemens Healthineers to Imaginostics marks a pivotal moment for MAGNETOM MRI systems. Announced just yesterday, it fosters formal dialogue on technical and commercial pathways for Imaginostics' ImagiView and ImagiSight technologies.

These offerings aim to deliver quantitative MRI capabilities directly on MAGNETOM platforms. Unlike traditional qualitative imaging, quantitative MRI extracts numerical biomarkers from scans, enabling objective measurements of tissue properties and disease states.

Dr. Codi Gharagouzloo, Imaginostics' Scientific Founder and CSO, highlighted the potential to shift healthcare from reactive to preventative models. This aligns with MAGNETOM's reputation for high-field strength and advanced sequences used in hospitals across Germany, Austria, and Switzerland.

No binding agreements exist yet, but the endorsement evaluates compatibility within regulatory frameworks. For MAGNETOM users, this could mean seamless software upgrades enhancing workflow efficiency.

In DACH clinics, where MRI demand surges due to aging populations, such integrations address radiologist variability in interpretations. This promises standardized diagnostics, crucial for multicenter studies common in the region.

The timing coincides with Europe's push for precision medicine initiatives. Siemens Healthineers' move positions MAGNETOM at the forefront, potentially accelerating adoption in university hospitals like those in Munich and Vienna.

Exploratory talks focus on vascular applications, complementing MAGNETOM's strengths in cardiac and neuro imaging. Early disease detection through digital twins—virtual patient models—could redefine screening protocols.

Imaginostics emphasizes AI-driven insights from MRI data. This partnership exploration underscores Siemens Healthineers' strategy to ecosystem-build around its hardware leaders.

Quantitative MRI Transforms MAGNETOM Diagnostic Power

Quantitative MRI elevates MAGNETOM systems beyond visual image assessment. It converts scans into measurable data on blood flow, tissue stiffness, and inflammation levels.

Imaginostics' technology creates digital twins from these metrics. For instance, vascular digital twins simulate disease progression, aiding personalized treatment planning.

MAGNETOM's BioMatrix technology already adapts sequences to patient physiology. Layering quantitative tools amplifies this, improving reproducibility across scans.

In oncology, precise tumor quantification reduces false positives. For DACH's comprehensive cancer networks, this means fewer repeat exams and faster therapy starts.

Cardiology benefits from enhanced left-ventricular function analysis. Compressed Sensing, recently FDA-cleared for MAGNETOM Aera and Skyra, already slashes acquisition times; quantitative add-ons build on this speed.

Neurology applications target brain disorders with superior soft-tissue contrast. Quantitative biomarkers standardize progression tracking in Alzheimer's trials prevalent in German research hubs.

Liver and prostate imaging see gains too. MAGNETOM's high-resolution sequences paired with AI quantification support PI-RADS scoring consistency.

Clinicians gain actionable insights, not just pictures. This shift boosts scanner utilization, as protocols become more reliable and patient-friendly.

DACH radiologists, trained in evidence-based practices, stand to benefit most. Integration could set new standards in EANM guidelines.

Commercial Impact in Expanding MRI Markets

The interventional radiology market hits USD 32.93 billion this year, growing at 7.6% CAGR to USD 63.66 billion by 2035. MRI holds a 10% share, leading in precision procedures.

MAGNETOM systems excel in MRI-guided interventions like biopsies and embolizations. Quantitative enhancements improve real-time navigation, cutting procedure times.

Biopsy devices market reaches USD 5.08 billion by 2035, with MRI-guided segments at 8.91% CAGR. Prostate and breast applications favor MAGNETOM's compatibility.

DACH ambulatory surgical centers expand at 6.8% CAGR. Compact MAGNETOM models suit these minimally invasive setups, boosted by quantitative efficiency.

Service revenues rise from software updates. Analysts project 20-30% scanner utilization gains, reducing repeat scans.

Helium shortages highlight MAGNETOM's dry-cool innovations. Operational reliability amid supply chain issues appeals to cost-conscious European buyers.

Siemens Healthineers builds ecosystems, akin to past Cook Medical ties. Imaginostics fits this pattern, expanding MAGNETOM's addressable market.

In DACH, public tenders prioritize innovative tech. Quantitative MRI positions MAGNETOM favorably against GE and Philips rivals.

Rising MRI utilization at double-digit rates in Europe amplifies commercial stakes. Precision medicine reimbursements incentivize upgrades.

Technical Fit Across MAGNETOM Portfolio

MAGNETOM spans 1.5T to 7T systems, scalable for quantitative apps. Lower-field models suit ambulatory use; ultra-high for research.

BioMatrix Sensors auto-adjust for motion and breathing. Quantitative overlays leverage this for artifact-free biomarkers.

Vascular focus of Imaginostics complements cardiac packages. Digital twins simulate interventions, enhancing pre-procedure planning.

In radiation therapy, MAGNETOM leads with superior soft-tissue contrast for prostate, brain, liver targets. Quantitative data refines adaptive planning.

Head and neck cancer delineation improves, critical for conformal therapies. DACH proton centers demand such precision.

Compressed Sensing accelerates cardiac cine to 16 seconds, enabling free-breathing scans. Quantitative metrics quantify ventricular function objectively.

Integration respects existing workflows. DotGO Cockpit manages data, streamlining biomarker reporting.

Regulatory paths align, with CE marking for Europe. DACH clinics adopt swiftly via familiar Siemens support.

Future-proofing via myExam Companion protocols eases quantitative adoption. Radiographers train quickly on enhanced interfaces.

DACH Healthcare Context and Adoption Drivers

Germany's MRI installed base exceeds 1,000 units, with utilization up 12% yearly. Quantitative tools address capacity strains in university clinics.

Austria's telemedicine push favors digital twins for remote consults. Swiss precision medicine hubs test early adopters.

GKV reimbursements cover advanced MRI if biomarkers proven. Imaginostics trials could unlock funding streams.

Hospital consolidation favors scalable Siemens ecosystems. MAGNETOM's uptime exceeds 99%, vital for high-volume sites.

Workforce shortages hit radiology; AI quantification eases interpretive burden. Younger DACH radiologists embrace tech integrations.

EU MDR compliance strengthens Siemens' position. Quantitative modules navigate approvals efficiently.

Patient outcomes improve with earlier detection. Vascular disease burdens DACH demographics, making biomarkers timely.

Competitive tenders in Bavaria and Zurich spotlight innovation. MAGNETOM's endorsement edges out alternatives.

Investor Context for Siemens Healthineers

Siemens Healthineers (DE000SHL1006) focuses on imaging growth amid Varian integration. MAGNETOM advancements support mid-single-digit revenue targets.

DACH represents key revenue from installed base services. Partnerships like Imaginostics signal pipeline strength without immediate dilution.

Market reacts positively to ecosystem news, lifting sentiment. Precision diagnostics align with 2026 guidance emphasizing recurring revenues.

Volatility tied to macro healthcare spends, but MRI resilience shines. Investors eye Q2 updates for collaboration progress.

Strategic positioning counters helium risks via dry-tech. Long-term, quantitative MRI bolsters moat in 7% CAGR sector.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.